@article{4a222db2ded94a2481c8bc777ddf9d10,
title = "PET/CT imaging with an 18F-labeled galactodendritic unit in a Galectin-1–overexpressing orthotopic bladder cancer model",
abstract = "Galectins are carbohydrate-binding proteins overexpressed in bladder cancer (BCa) cells. Dendritic galactose moieties have a high affinity for galectin-expressing tumor cells. We radiolabeled a dendritic galactose carbohydrate with 18F (18F-labeled galactodendritic unit 4) and examined its potential in imaging urothelial malignancies. Methods: The 18F-labeled first-generation galactodendritic unit 4 was obtained from its tosylate precursor. We conducted in vivo studies in a galectin-expressing UMUC3 orthotopic BCa model to determine the ability of 18F-labeled galactodendritic unit 4 to image BCa. Results: Intravesical administration of 18F-labeled galactodendritic unit 4 allowed specific accumulation of the carbohydrate radiotracer in galectin-1–overexpressing UMUC3 orthotopic tumors when imaged with PET. The 18F-labeled galactodendritic unit 4 was not found to accumulate in nontumor murine bladders. Conclusion: The 18F-labeled galactodendritic unit 4 and similar analogs may be clinically relevant and exploitable for PET imaging of galectin-1–overexpressing bladder tumors.",
keywords = "Bladder cancer, Dendritic carbohydrate, F-radiochemistry, Galectins, PET/CT imaging",
author = "Pereira, {Patricia M.R.} and Sheryl Roberts and Fl{\'a}vio Figueira and Tom{\'e}, {Jo{\~a}o P.C.} and Thomas Reiner and Lewis, {Jason S.}",
note = "Funding Information: The MSKCC Small Animal Imaging Core Facility and the Radiochemistry and Molecular Imaging Probe Core were supported by NIH grant P30 CA08748. This study was supported in part by the Geoffrey Beene Cancer Research Center of MSKCC (Jason Lewis), NIH NCI R35 CA232130 (Jason Lewis), the Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Center for Experimental Therapeutics of Memorial Sloan Kettering Cancer Center, and a Tow Foundation Postdoctoral Fellowship (Patricia Pereira), as well as by Fundaxc{\~a}o para a Ci{\^e}ncia e a Tecnologia (FCT, Portugal), the European Union, QREN, FEDER through Programa Operacional Factores de Competitividade (COMPETE), QOPNA (FCT UID/QUI/00062/2019), and CQE (FCT UID/QUI/0100/2019) research units, which are financed by national funds through the FCT/MEC and, when appropriate, cofinanced by FEDER under the PT2020 Partnership Agreement. The research contract of Fl{\'a}vio Figueira (REF-168-89-ARH/2018) is funded by national funds (OE) through FCT. No other potential conflict of interest relevant to this article was reported. Publisher Copyright: {\textcopyright} 2020 by the Society of Nuclear Medicine and Molecular Imaging",
year = "2020",
month = sep,
day = "1",
doi = "10.2967/jnumed.119.236430",
language = "English",
volume = "61",
pages = "1369--1375",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
number = "9",
}